Cargando…

Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

BACKGROUND: Focal radiation therapy has gained of interest in treatment of patients with primary prostate cancer (PCa). The question of how to define the intraprostatic boost volume is still open. Previous studies showed that multiparametric MRI (mpMRI) or PSMA PET alone could be used for boost volu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamboglou, Constantinos, Thomann, Benedikt, Koubar, Khodor, Bronsert, Peter, Krauss, Tobias, Rischke, Hans C., Sachpazidis, Ilias, Drendel, Vanessa, Salman, Nasr, Reichel, Kathrin, Jilg, Cordula A., Werner, Martin, Meyer, Philipp T., Bock, Michael, Baltas, Dimos, Grosu, Anca L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930745/
https://www.ncbi.nlm.nih.gov/pubmed/29716617
http://dx.doi.org/10.1186/s13014-018-1036-8
_version_ 1783319528973795328
author Zamboglou, Constantinos
Thomann, Benedikt
Koubar, Khodor
Bronsert, Peter
Krauss, Tobias
Rischke, Hans C.
Sachpazidis, Ilias
Drendel, Vanessa
Salman, Nasr
Reichel, Kathrin
Jilg, Cordula A.
Werner, Martin
Meyer, Philipp T.
Bock, Michael
Baltas, Dimos
Grosu, Anca L.
author_facet Zamboglou, Constantinos
Thomann, Benedikt
Koubar, Khodor
Bronsert, Peter
Krauss, Tobias
Rischke, Hans C.
Sachpazidis, Ilias
Drendel, Vanessa
Salman, Nasr
Reichel, Kathrin
Jilg, Cordula A.
Werner, Martin
Meyer, Philipp T.
Bock, Michael
Baltas, Dimos
Grosu, Anca L.
author_sort Zamboglou, Constantinos
collection PubMed
description BACKGROUND: Focal radiation therapy has gained of interest in treatment of patients with primary prostate cancer (PCa). The question of how to define the intraprostatic boost volume is still open. Previous studies showed that multiparametric MRI (mpMRI) or PSMA PET alone could be used for boost volume definition. However, other studies proposed that the combined usage of both has the highest sensitivity in detection of intraprostatic lesions. The aim of this study was to demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of radiation therapy dose painting using (68)Ga-HBED-CC PSMA PET/CT, mpMRI or the combination of both in primary PCa. METHODS: Ten patients underwent PSMA PET/CT and mpMRI followed by prostatectomy. Three gross tumour volumes (GTVs) were created based on PET (GTV-PET), mpMRI (GTV-MRI) and the union of both (GTV-union). Two plans were generated for each GTV. Plan95 consisted of whole-prostate IMRT to 77 Gy in 35 fractions and a simultaneous boost to 95 Gy (Plan95(PET)/Plan95(MRI)/Plan95(union)). Plan80 consisted of whole-prostate IMRT to 76 Gy in 38 fractions and a simultaneous boost to 80 Gy (Plan80(PET)/Plan80(MRI)/Plan80(union)). TCPs were calculated for GTV-histo (TCP-histo), which was delineated based on PCa distribution in co-registered histology slices. NTCPs were assessed for bladder and rectum. RESULTS: Dose constraints of published protocols were reached in every treatment plan. Mean TCP-histo were 99.7% (range: 97%–100%) and 75.5% (range: 33%–95%) for Plan95(union) and Plan80(union), respectively. Plan95(union) had significantly higher TCP-histo values than Plan95(MRI) (p = 0.008) and Plan95(PET) (p = 0.008). Plan80(union) had significantly higher TCP-histo values than Plan80(MRI) (p = 0.012), but not than Plan80(PET) (p = 0.472). Plan95(MRI) had significantly lower NTCP-rectum than Plan95(union) (p = 0.012). No significant differences in NTCP-rectum and NTCP-bladder were observed for all other plans (p > 0.05). CONCLUSIONS: IMRT dose escalation on GTVs based on mpMRI, PSMA PET/CT and the combination of both was feasible. Boosting GTV-union resulted in significantly higher TCP-histo with no or minimal increase of NTCPs compared to the other plans. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13014-018-1036-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5930745
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59307452018-05-09 Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference Zamboglou, Constantinos Thomann, Benedikt Koubar, Khodor Bronsert, Peter Krauss, Tobias Rischke, Hans C. Sachpazidis, Ilias Drendel, Vanessa Salman, Nasr Reichel, Kathrin Jilg, Cordula A. Werner, Martin Meyer, Philipp T. Bock, Michael Baltas, Dimos Grosu, Anca L. Radiat Oncol Research BACKGROUND: Focal radiation therapy has gained of interest in treatment of patients with primary prostate cancer (PCa). The question of how to define the intraprostatic boost volume is still open. Previous studies showed that multiparametric MRI (mpMRI) or PSMA PET alone could be used for boost volume definition. However, other studies proposed that the combined usage of both has the highest sensitivity in detection of intraprostatic lesions. The aim of this study was to demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of radiation therapy dose painting using (68)Ga-HBED-CC PSMA PET/CT, mpMRI or the combination of both in primary PCa. METHODS: Ten patients underwent PSMA PET/CT and mpMRI followed by prostatectomy. Three gross tumour volumes (GTVs) were created based on PET (GTV-PET), mpMRI (GTV-MRI) and the union of both (GTV-union). Two plans were generated for each GTV. Plan95 consisted of whole-prostate IMRT to 77 Gy in 35 fractions and a simultaneous boost to 95 Gy (Plan95(PET)/Plan95(MRI)/Plan95(union)). Plan80 consisted of whole-prostate IMRT to 76 Gy in 38 fractions and a simultaneous boost to 80 Gy (Plan80(PET)/Plan80(MRI)/Plan80(union)). TCPs were calculated for GTV-histo (TCP-histo), which was delineated based on PCa distribution in co-registered histology slices. NTCPs were assessed for bladder and rectum. RESULTS: Dose constraints of published protocols were reached in every treatment plan. Mean TCP-histo were 99.7% (range: 97%–100%) and 75.5% (range: 33%–95%) for Plan95(union) and Plan80(union), respectively. Plan95(union) had significantly higher TCP-histo values than Plan95(MRI) (p = 0.008) and Plan95(PET) (p = 0.008). Plan80(union) had significantly higher TCP-histo values than Plan80(MRI) (p = 0.012), but not than Plan80(PET) (p = 0.472). Plan95(MRI) had significantly lower NTCP-rectum than Plan95(union) (p = 0.012). No significant differences in NTCP-rectum and NTCP-bladder were observed for all other plans (p > 0.05). CONCLUSIONS: IMRT dose escalation on GTVs based on mpMRI, PSMA PET/CT and the combination of both was feasible. Boosting GTV-union resulted in significantly higher TCP-histo with no or minimal increase of NTCPs compared to the other plans. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13014-018-1036-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-02 /pmc/articles/PMC5930745/ /pubmed/29716617 http://dx.doi.org/10.1186/s13014-018-1036-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zamboglou, Constantinos
Thomann, Benedikt
Koubar, Khodor
Bronsert, Peter
Krauss, Tobias
Rischke, Hans C.
Sachpazidis, Ilias
Drendel, Vanessa
Salman, Nasr
Reichel, Kathrin
Jilg, Cordula A.
Werner, Martin
Meyer, Philipp T.
Bock, Michael
Baltas, Dimos
Grosu, Anca L.
Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
title Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
title_full Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
title_fullStr Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
title_full_unstemmed Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
title_short Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
title_sort focal dose escalation for prostate cancer using (68)ga-hbed-cc psma pet/ct and mri: a planning study based on histology reference
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930745/
https://www.ncbi.nlm.nih.gov/pubmed/29716617
http://dx.doi.org/10.1186/s13014-018-1036-8
work_keys_str_mv AT zamboglouconstantinos focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT thomannbenedikt focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT koubarkhodor focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT bronsertpeter focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT krausstobias focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT rischkehansc focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT sachpazidisilias focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT drendelvanessa focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT salmannasr focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT reichelkathrin focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT jilgcordulaa focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT wernermartin focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT meyerphilippt focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT bockmichael focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT baltasdimos focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference
AT grosuancal focaldoseescalationforprostatecancerusing68gahbedccpsmapetctandmriaplanningstudybasedonhistologyreference